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Growth factor signaling is usually analyzed in isolation without considering the effect of ligand
occupancy of transmembrane proteins other than the growth factor receptors themselves. In
smooth muscle cells, the transmembrane protein Src homology 2 domain containing protein
tyrosine phosphatase substrate-1 (SHPS-1) has been shown to be an important regulator of
insulin-like growth factor-I (IGF-I) signaling. SHPS-1 is phosphorylated in response to IGF-I,
leading to recruitment of Src homology 2 domain tyrosine phosphatase (SHP-2). Subsequently,
SHP-2 is transferred to IGF-I receptor and regulates the duration of IGF-I receptor phosphoryla-
tion. Whether ligand occupancy of SHPS-1 influences SHPS-1 phosphorylation or SHP-2 recruit-
ment, thereby altering growth factor signaling, is unknown. Previous studies have shown that
integrin associated protein (IAP) associates with SHPS-1. We undertook these studies to deter-
mine whether this interaction controlled SHPS-1 phosphorylation and/or SHP-2 recruitment and
thereby regulated IGF-I signaling. Disruption of IAP-SHPS-1 binding, by using an IAP monoclo-
nal antibody or cells expressing mutant forms of IAP that did not bind to SHPS-1, inhibited
IGF-I–stimulated SHPS-1 phosphorylation and SHP-2 recruitment. This was associated with a lack
of SHP-2 transfer to IGF-I receptor and sustained receptor phosphorylation. This resulted in an
inability of IGF-I to stimulate sustained mitogen-activated protein kinase activation, cell prolif-
eration, and cell migration. The effect was specific for IGF-I because disruption of the IAP–SHPS-1
interaction had no effect on platelet-derived growth factor-stimulated SHPS-1 phosphorylation or
cell migration. In summary, our results show that 1) ligand occupancy of SHPS-1 is a key
determinant of its ability to be phosphorylated after IGF-I stimulation, and 2) the interaction
between IAP and SHPS-1 is an important regulator of IGF-I signaling because disruption of the
results in impaired SHP-2 recruitment and subsequent inhibition of IGF-I–stimulated cell prolif-
eration and migration.
INTRODUCTION
Insulin-like growth factor-I (IGF-I) is a potent stimulator of
smooth muscle cell (SMC) migration and proliferation (Jones
et al., 1996). There is increasing evidence to show that the
ability of IGF-I to initiate intracellular signaling is regulated
not only by its association with its own transmembrane
receptor but also by other transmembrane proteins such as
the V3 integrin (Zheng and Clemmons, 1998; Maile and
Clemmons, 2002a), integrin associated protein (IAP) (Maile
et al., 2002), and Src homology 2 domain containing protein
tyrosine phosphatase substrate-1 (SHPS-1) (Maile and Clem-
mons, 2002b).
SHPS-1 was identified as a tyrosine-phosphorylated pro-
tein that binds to SHP-2 in v-SRC–transformed fibroblasts
(Noguchi et al., 1996) and in insulin-stimulated Chinese
hamster ovary cells (Fujioka et al., 1996). The cytoplasmic
region of SHPS-1 contains two immunoreceptor tyrosine-
based inhibitory motifs (Kharitonenkov et al., 1997) that are
phosphorylated in response to various mitogenic stimuli
(Noguchi et al., 1996; Kharitonenkov et al., 1997; Stofega et al.,
1998; Maile and Clemmons, 2002b) and integrin-mediated
cell attachment (Fujioka et al., 1996; Noguchi et al., 1996;
Takada et al., 1998). This phosphorylation generates binding
sites for the recruitment and activation of Src homology 2
domain tyrosine phosphatase (SHP-2) that in turn dephos-
phorylates SHPS-1 (Fujioka et al., 1996; Noguchi et al., 1996;
Kharitonenkov et al., 1997; Takada et al., 1998).
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In stably attached smooth muscle cells (SMCs), SHP-2 is
localized to a site close to the cell membrane from where it
is transferred to the SHPS-1 after IGF-I–stimulated SHPS-1
phosphorylation (Maile and Clemmons, 2002b). This recruit-
ment of SHP-2 is followed by the dephosphorylation of
SHPS-1 and the transfer of SHP-2 to the IGF-I receptor
(IGF-IR) where it subsequently dephosphorylates this sub-
strate (Maile and Clemmons, 2002b). The importance of
SHPS-1 phosphorylation in regulating IGF-IR phosphoryla-
tion has been demonstrated in cells expressing a truncated
form of SHPS-1 in which the SHP-2 binding sites have been
deleted. In these cells, transfer of SHP-2 to both SHPS-1 and
the IGF-IR is blocked and sustained phosphorylation of both
molecules is evident (Maile and Clemmons, 2002b).
IAP was first identified by its ability to associate with
V3 (Brown et al., 1990) and to increase the affinity of the
integrin for its ligands (Brown et al., 1990). IAP consists of a
N-terminal (extracellular) Ig variable type domain followed
by five membrane spanning hydrophobic helices and a cy-
toplasmic tail (Rosales et al., 1992).
IAP has been shown to bind to SHPS-1 (Jiang et al., 1999;
Seiffert et al., 1999; (Babic et al., 2000; Oldenborg et al., 2000;
Vernon-Wilson et al., 2000; Yoshida et al., 2002). The amino
terminal Ig domain of IAP and the extracellular Ig variable
domain of SHPS-1 are sufficient for their physical interaction
(Seiffert et al., 1999; Vernon-Wilson et al., 2000). Although
disruption of IAP–SHPS-1 interaction has been shown to
result in changes in cellular function (Babic et al., 2000;
Oldenborg et al., 2000; Vernon-Wilson et al., 2000) the effect
of IAP binding to SHPS-1 on growth factor-stimulated
SHPS-1 phosphorylation and SHP-2 recruitment has not
been reported. The first aim of these studies was to deter-
mine whether an association between IAP and SHPS-1 could
be detected in SMCs. Second, we wished to determine the
effect of IAP association with SHPS-1 on IGF-I–stimulated
SHPS-1 phosphorylation and subsequent SHP-2 recruitment
and then to examine the effect of disrupting the interaction
between IAP and SHPS-1 on IGF-IR–dependent biological
actions in SMCs.
MATERIALS AND METHODS
Human IGF-I was a gift from Genentech (South San Francisco, CA)
and polyvinyldifluoride membrane (Immobilon P) was purchased
from Millipore (Bedford, MA). Autoradiographic film was obtained
from Eastman Kodak (Rochester, NY). Fetal bovine serum, Dulbec-
co’s modified medium, penicillin, and streptomycin were pur-
chased from Invitrogen (Carlsbad, CA). The IGF-IR  chain anti-
body and the monoclonal phosphotyrosine antibody (PY99) were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The
polyclonal SHP-2 and SHPS-1 antibodies were purchased from
Transduction Laboratories (Lexington, KY). The monoclonal anti-
body (mAb) against IAP, B6H12, was purified using protein G-
Sepharose from Pierce Chemical (Rockford, IL) according to the
manufacturer’s protocol from B cell hybridoma-conditioned media
that had been obtained from cells purchased from the American
Type Culture Collection (Manassas, VA). The anti FLAG mAb was
purchased from Sigma-Aldrich (St. Louis, MO). The antibody
against the dual phosphorylated (active) form of p42/p44 mitogen-
activated protein kinase (MAPK) and the antibody against total
p42/p44 MAPK protein were purchased from Cell Signaling Tech-
nology (Beverly, MA). A mouse isotype-specific control (IgGi) was
purchased from Sigma-Aldrich, and polyclonal antibody control
sera was obtained in house after a central ear artery bleed of a
nonimmunized rabbit. All other reagents were purchased from
Sigma-Aldrich unless otherwise stated.
Porcine aortic SMCs (pSMCs) were isolated as described previ-
ously (Gockerman et al., 1995) and maintained in Dulbecco’s mod-
ified medium supplemented with glucose (4.5 gm/l), penicillin (100
U/ml), streptomycin (100 g/ml) (DMEM-H), and 10% fetal bovine
serum (FBS) in 10-cm tissue culture plates (Falcon Laboratory,
Franklin Lakes NJ). The cells were used between passage 5 and 16.
Generation of Expression Vectors
Full-Length Porcine IAP with a C-Terminal FLAG Epitope (IAPfl).
Full-length porcine IAP was cloned by reverse transcription-poly-
merase chain reaction (PCR) from a cDNA library that had been
derived from pSMCs that had been isolated as described previously
(Gockerman et al., 1995). The 5 primer sequence 5-ATGTGGCCCT-
GGTGGTC corresponded to nucleotides 121–139 of the porcine
sequence. The 3-primer sequence was complementary to nucleo-
tides 1005–1030 with the addition of bases encoding the FLAG
sequence (underlined) and a stop codon. The sequence was 5-
TCATTTGTCGTCGTCGTCTTTGTAGTCGGTTGTATAGTCT 3.
After sequencing, the cDNA was cloned into the pcDNA V5 his 3.1
vector (Invitrogen).
IAP with Truncation of Extracellular Domain at Residue 135 and
Containing a C-terminal FLAG Epitope (IAPcyto). The pcDNA V5
his 3.1 vector containing the IAPfl cDNA sequence was linearized
and the mutant form of IAP was generated using PCR with a 5
oligonucleotide encoding bases 527–556 (5 TCTCCAAAT-
GAAAAATCCTCATTGTTATT 3) and the same 3 oligonucleotide
that was used to generate the IAPfl. The PCR product was cloned in
to pcDNA V5 his 3.1.
IAP in which Cysteine 33 and 261 Are Substituted with Serine
Residues Containing a C-Terminal FLAG Epitope (IAPc-s). The
IAPfl cDNA was subcloned in a pRcRSV expression vector and it
was used as a template to perform single-stranded mutagenesis to
incorporate the two substitutions. The pRcRSV vector contains a
neomycin derivative (G418) resistance gene and a bacteriophage
origin of replication (F1) gene that permits direct single-stranded
mutagenesis of the cDNA. Two oligonucleotides encoding the base
substitutions were used. They were C33S, complementary to nucle-
otides 204–225, except for a base substitution to encode a serine
(underlined) 5 GTAACAGTTGTATTGGAAACGGTGAATTCTA
3; and C261S, complementary to nucleotides 888–918, except for
the base substitution to encode the serine residue (underlined) 5
CCATGCACTGGGGTAGACTCTGAGACGCAG. After sequenc-
ing, the DNA constructs were subcloned into pMEP4 expression
vector (Invitrogen).
Transfection of pSMCs
Cells that had been grown to 70% confluence were transfected with
one of three IAP cDNA constructs as described previously (Imai et
al., 1997). Hygromycin-resistant pSMCs were selected and main-
tained in DMEM-H containing 15% FBS and 100 g/ml hygromycin
as described previously (Imai et al., 1997). Expression of protein
levels was assessed by preparing whole cell lysates and visualizing
FLAG protein expression by immunoblotting as described below.
Transfected pSMCs that were obtained from two transfections per-
formed independently were used in subsequent experiments and
the results that were obtained were consistent between the two
groups of cells.
IGF-I Stimulation of Cells
Quiescent SMCs were pretreated with either B6H12 or IgGi (both at
a concentration of 4 g/ml) in serum free medium (SFM). Cells
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were then exposed to IGF-I (100 ng/ml) or to platelet-derived
growth factor (PDGF) (10 ng/ml) for appropriate lengths of time.
Immunoprecipitation and Immunoblotting
Tyrosine phosphorylation and association between proteins was
determined by immunoprecipitation and immunoblotting of cell
lysates as we have described previously (Maile and Clemmons,
2002a). The lysis buffer contained: 50 mM Tris-HCl (pH 7.5), 150
mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 1 mM EGTA
plus 1 mM sodium orthovanadate, 1 mM sodium fluoride, 1 mM
phenylmethylsulfonyl fluoride, 1 g/ml pepstatin A, 1 g/ml leu-
peptin, 1 g/ml aprotinin. For the immunoprecipitation cell lysates
were incubated overnight at 4°C with the appropriate antibody;
IGF-IR, SHPS-1 nonimmune rabbit serum as a control or B6H12 or
IgGi by using a 1:500 dilution. For immunoblotting, membranes
were incubated with one of six primary antibodies (IGF-IR, SHP-2,
SHPS-1, PY99, B6H12 or FLAG, all using a 1:500 dilution) overnight
at 4°C. Binding of the peroxidase labeled secondary antibody was
visualized using enhanced chemiluminescence following the man-
ufacturer’s instructions (Pierce Chemical), and the immune com-
plexes were detected by exposure to autoradiographic film or by
using the GeneGnome charge-coupled device imaging system (Syn-
gene, Cambridge, UK).
Chemiluminescent images obtained were scanned using a Du-
oScan T1200 (AGFA Brussels, Belgium), and band intensities of the
scanned images were analyzed using NIH Image, version 1.61. The
Student’s t test was used to compare differences between treat-
ments. The results that are shown are representative of at least three
separate experiments
Assessment of p42/p44 MAPK Activation
The effect of B6H12 on IGF-I activation of p42/44 MAPK was
determined, as we have described previously (Imai and Clemmons,
1999), by immunoblotting of cell lysates with an antibody that is
specific for the dual phosphorylated (threonine202 and tyrosine204)
protein (at a dilution of 1:1000).
Cell Wounding and Migration Assay
Wounding of cell monolayers that had been grown to confluence
over 7 days was performed as described previously (Jones et al.,
1996). The wounded monolayers were incubated with SFM (plus
0.2% FBS) with or without 100 ng/ml IGF-I or PDGF (10 ng/ml).
The cells were then fixed and stained (Diff Quick; Dade Behring,
Newark, DE), and the number of cells migrating into the wound
area was counted. At least five of the previously selected 1 mm areas
at the edge of the wound were counted for each data point.
Assessment of Cell Proliferation
The effect of B6H12 or an IgGi (4 g/ml) on IGF-I–stimulated cell
proliferation was carried out essentially as we have described pre-
viously (Nam et al., 2002). A 2-h preincubation in the presence or
absence of B6H12 or an IgGi (4 g/ml) was followed by the addition
of IGF-I (100 ng/ml). Cells were incubated for 48 h, and final cell
number in each well determined. Each treatment was performed in
triplicate The Student’s t test was used to compare differences
between treatments. The results that are shown represent the mean
( SEM) from three separate experiments.
RESULTS
IAP Associates with SHPS-1 in Stably Attached
pSMCs via Its Extracellular Domain
Figure 1A shows that in stably attached quiescent SMCs,
there is detectable association between IAP and SHPS-1 as
determined by coimmunoprecipitation experiments with
both anti-IAP and anti SHPS-1 antibodies for immunopre-
cipitation.
To investigate the role of IAP association with SHPS-1 in
IGF-IR signaling, we developed two experimental models in
which we disrupted the association between IAP and
SHPS-1. The first approach was to use an anti-IAP monoclo-
nal, B6H12, to interfere with the binding of the two proteins.
This antibody has been shown to be specific for IAP (Brown
et al., 1990). Figure 1B shows that after incubation of quies-
cent pSMCs with the anti-IAP mAb (B6H12), the interaction
between IAP and SHPS-1 is significantly reduced (a 75 
7.5% reduction [mean  SEM, n  3, p  0.05]). Preincuba-
tion with the IgGi control had no effect on the association
between the two proteins.
Figure 1. Coprecipitation of IAP with
SHPS-1 and disruption with anti IAP anti-
body. (A) Cell lysates were either immuno-
precipitated with an anti-IAP antibody and
coprecipitation of SHPS-1 determined by im-
munoblotting with anti-SHPS-1 antiserum or
they were immunoprecipitated with anti
SHPS-1 antibody and coprecipitation of IAP
determined by immunoblotting with an anti-
IAP antibody. As a control cell lysates were
also immunoprecipitated with nonimmune
rabbit serum (IgG) and immunoblotted with
an anti-IAP antibody. (B) Quiescent pSMCs
were incubated for 2 h  the addition of the
anti-IAP mAb, B6H12 or IgGi (both at 4 g/
ml). Coprecipitation of IAP with SHPS-1 was
then determined by immunoprecipitating with an SHPS-1 antibody and immunoblotting with an anti-IAP antibody. The amount of SHPS-1
protein in each lane is shown in the lower row. (C) Expression of FLAG-labeled IAP and association with SHPS-1. Top, expression of
FLAG-labeled IAP was determined by immunoblotting whole-cell lysates from cells transfected with each of the IAP cDNA constructs by
using an anti-FLAG antibody. The results as scanning units are lane 1, 38,018; lane 2, 39,274; and lane 3, 46,779. Bottom, cell lysates were
immunoprecipitated with an anti-SHPS-1 antibody and then coprecipitation of FLAG-labeled IAP was determined by immunoblotting with
an anti-FLAG antibody. The amount of SHPS-1 that was immunoprecipitated in each lane is shown in the lower row. The results shown in
this figure are representative of at least three independent experiments with similar results.
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As we have reported previously, the B6H12 antibody can
also disrupt IAP association with V3 and thereby alter
IGF-I signaling (Maile et al. 2002). The binding between IAP
and SHPS-1 specifically requires an intact disulfide bond in
IAP between cysteine 33 in the extracellular domain and
cysteine 261 within the putative transmembrane domain
(Rebres et al., 2001). If this bond is disrupted by mutagenesis,
the interaction of IAP with V3 is preserved but binding to
SHPS-1 is eliminated. We therefore generated and expressed
a mutant form of IAP in which the association between IAP
and SHPS-1 would be predicted to be specifically disrupted,
whereas the association with V3 would be preserved.
This allowed us to distinguish between the effects of dis-
rupting IAP-SHPS-1 binding from disrupting IAP-V3.
Additonally, we expressed a second mutant form of IAP in
which the entire extracellular domain was truncated. Figure
1C (top) shows the level of expression of three forms of IAP
that were used in subsequent experiments. The results show
that the cells are expressing equal amounts of 1) FLAG-
tagged full-length IAP (IAPfl); 2) the FLAG-tagged mutant
form of IAP in which the two cysteine residues 33 and 261
had been substituted with serines (IAPc-s); and 3) the FLAG-
tagged mutant form of IAP in which the complete extracel-
lular domain has been deleted at amino acid residue 135
(IAPcyto).
To determine whether mutagenesis disrupted IAP associ-
ation with SHPS-1, we immunoprecipitated SHPS-1 from
each of these cell populations and immunoblotted with an
anti-FLAG antibody. A representative experiment shown in
Figure 1C shows that disruption of the extracellular domain
of IAP alters its ability to associate with SHPS-1. When the
results from three experiments were analyzed, it was deter-
mined that expression of IAPcyto resulted in a significant
88  6.4% (mean  SEM, n  3, p  0.05) reduction in IAP
association with SHPS-1 compared with cells expressing
IAPfl. Because truncation of the extracellular domain of IAP
also disrupts its association with V3, we analyzed the
SHPS-1–IAP interaction in cells expressing the IAPc-s mu-
tation. In cells expressing IAPc-s, there was a significant
81  4.5% (mean  SEM, n  3 p  0.05) reduction in IAP
association with SHPS-1 compared with cells expressing
IAPfl. The control immunoblots show that similar levels of
SHPS-1 were immunoprecipitated.
Blocking IAP–SHPS-1 Association Inhibits IGF-I–
Stimulated SHPS-1 Phosphorylation and SHP-2
Recruitment
To determine the functional consequences of the loss of this
physical association between IAP and SHPS-1, we examined
SHPS-1 phosphorylation in response to IGF-I in wild-type
cells pretreated with the anti-IAP mAb, B6H12. A represen-
tative experiment is shown in Figure 2A. When cells were
exposed to SFM or control IgGi, IGF-I increased SHPS-1
phosphorylation by 4.1  0.9 (mean  SEM n  3)-fold and
4.9  1.45 (mean  SEM, n  3), respectively. In contrast, in
cells exposed to B6H12 IGF-I stimulated phosphorylation
0.93  0.12 (mean  SEM, n  3)-fold and this was signif-
icantly reduced (p  0.05). This reduction in SHPS-1 phos-
phorylation in the presence of B6H12 is associated with a
significant decrease (p  0.05) in IGF-I–stimulated recruit-
ment of SHP-2 to SHPS-1. Whereas SHP-2 association was
increased 14  1.5-fold increase in control cells and 17.3 
3.85-fold in cells preincubated with the IgGi (mean  SEM,
n  3) after B6H12 exposure the increase was only 1.8  1.1
(mean  SEM, n  3)-fold. When the results of the cells
exposed to B6H12 were compared with the SFM or IgGi
control cultures, the differences were significant (p  0.05).
The Extracellular Domain of IAP Is Required for
IGF-I–stimulated SHPS-1 Phosphorylation and
SHP-2 Recruitment
To confirm that blocking IAP binding to SHPS-1 inhibited
IGF-I–stimulated SHPS-1 phosphorylation, the ability of
IGF-I to stimulate SHPS-1 phoshorylation in cells expressing
the mutant forms of IAP was compared with cells express-
ing wild-type IAP. The results from a representative exper-
iment are shown in Figure 2B. IGF-I stimulated a 3.6  0.8
(mean  SEM, n  3)-fold increase in SHPS-1 phosphoryla-
tion in cells expressing IAPfl. In contrast, cells expressing the
IAPcyto or the IAPc-s mutant had a 1.03  0.08- and 1.03 
0.13 (mean  SEM, n  3)-fold increases in SHPS-1 phos-
phorylation in response to IGF-I. These responses were sig-
nificantly less than in cells expressing IAPfl (p  0.05).
Consistent with the results obtained using B6H12 the lack
of SHPS-1 phosphorylation observed in the cells expressing
the mutant forms of IAP is associated with an inhibition in
SHP-2 recruitment to SHPS-1 in response to IGF-I (Figure
2B) (p  0.05 when the results obtained will cells expressing
either mutant was compared with cells expressing IAPfl).
Because SHPS-1 has been shown to be phosphorylated in
response to several growth factors, we wished to investigate
the specificity of the requirement of IAP binding to SHPS-1.
Figure 2C shows that PDGF induces a 5. 3  1 (mean  SEM,
n  2)-fold increase in SHPS-1 phosphorylation after 5-min
exposure in cells expressing IAPfl. However, in contrast to
IGF-I, PDGF stimulated a 6.8  0.8 (mean  SEM, n 
2)-fold increase in cells expressing IAPc-s and this was not
significantly different compared with the response of the
IAPfl cells.
The Association between the Extracellular Domain
of IAP and SHPS-1 Regulates the Duration of IGF-
IR Phosphorylation via Its Modulation of SHP-2
Recruitment
Phosphorylation of SHPS-1 is required for SHP-2 transfer to
the IGF-IR and thereby regulates the duration of IGF-IR
phosphorylation (Maile and Clemmons, 2002b); therefore,
we examined recruitment of SHP-2 to IGF-IR and the dura-
tion of IGF-IR phosphorylation in cells pretreated with
B6H12 and in cells expressing the mutant forms of IAP. In
control cells IGF-I stimulates a 4.3  0.5 (mean  SEM, n 
3)-fold increase in SHP-2 recruitment to the IGF-I receptor
after a 10-min exposure to IGF-I (Figure 3A). However, in
cells pretreated with B6H12, there is no significant increase
seen in SHP-2 recruitment to IGF-IR (1.1  0.05-fold;
mean  SEM, n  3), and this response to IGF-I is signifi-
cantly lower compared with control or IgGi-treated cells
(p  0.05). Consistent with our previous results (Maile and
Clemmons, 2002b) the recruitment of SHP-2 to the IGF-IR
precedes a 50  0.06% reduction in IGF-I receptor phosphor-
ylation that is observed after 20 min IGF-I stimulation. Fol-
lowing B6H12 pretreatment there is no significant difference
L.A. Maile et al.
Molecular Biology of the Cell3522
Figure 2. (A) SHPS-1 phosphoryla-
tion and SHP-2 recruitment to SHPS-1
in response to IGF-I after disruption of
the association between IAP and
SHPS-1 by the anti-IAP antibody
B6H12. Quiescent cells were incubated
for 2 h  B6H12 antibody or IgGi (both
at 4 g/ml) and then exposed to IGF-I
(100 ng/ml) as indicated. Cell lysates
were immunoprecipitated with an an-
ti-SHPS-1 antibody and then SHPS-1
phosphorylation was determined by
immunoblotting with a pTyr. The as-
sociation of SHP-2 with SHPS-1 was
visualized by immunoblotting by us-
ing an anti SHP-2 antibody. The
amount of SHPS-1 protein in each lane
is shown in the lower row. The fold
increase in SHPS-1 phosphorylation
and SHP-2 recruitment after IGF-I
stimulation as determined by scanning
densitometric analysis of Western im-
munoblots from three separate experi-
ments is shown. **p  0.05 when the
response to IGF-I of cells preincubated
with B6H12 is compared with the
IGF-I response in cells preincubated in
SFM or control IgGi. (B) SHPS-1 phos-
phorylation and SHP-2 recruitment in
response to IGF-I after disruption of
the association between IAP and
SHPS-1 in cells expressing mutated
forms of IAP. Cells were exposed to
IGF-I (100 ng/ml) for various periods.
Cell lysates were immunoprecipitated
with an anti-SHPS-1 antibody and
SHPS-1 phosphorylation was deter-
mined by immunoblotting with an an-
ti-phosphotyrosine antibody (pTyr).
The association of SHP-2 was visual-
ized by immunoblotting using an anti
SHP-2 antibody. The amount of
SHPS-1 protein in each lane is shown
in the lower row. The increase in
SHPS-1 phosphorylation and SHP-2
recruitment after IGF-I stimulation as
determined by scanning densitometric
analysis of Western immunoblots
from three separate experiments is
shown. **p  0.05 when the response
of cells expressing either of the mutant
forms of IAP to IGF-I is compared with
the IGF-I response in cells expressing
IAPfl. (C) SHPS-1 phosphorylation in
response to PDGF. Cells were exposed
to PDGF (10 ng/ml) for 5 min. After
cell lysis and immunoprecipitation
with an anti-SHPS-1 antibody, SHPS-1
phosphorylation was determined by
immunoblotting with a pTyr.
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Figure 3. IGF-IR phosphorylation time course and SHP-2 recruitment after disruption of the interaction between IAP and SHPS-1. (A) Quiescent
cells were incubated  B6H12 or IgGi (4 g/ml) and then exposed to IGF-I (100 ng/ml) for various lengths of time. After lysis and immunopre-
cipitation with an anti-IGF-IR antibody phosphorylation of the receptor was determined by immunoblotting with a pTyr. The association of SHP-2
was determined by immunoblotting with an anti SHP-2 antibody. The amount of IGF-IR protein in each lane is shown in the lower row. The level
of tyrosine phosphorylation of IGF-IR as a percentage of maximum phosphorylation detected as determined by scanning densitometric analysis
of Western immunoblots from three separate experiments is shown. The increase in SHP-2 recruitment after IGF-I stimulation as determined by
scanning densitometry analysis of Western immunoblots from three separate experiments is also shown. **p  0.05 when the response of cells
preincubated with B6H12 to IGF-I is compared with cells preincubated in SFM alone or containing control IgGi. (B) Cells were incubated with IGF-I
(100 ng/ml) for various times. After lysis and immunoprecipitation with an anti-IGF-IR antibody, phosphorylation of the receptor was determined
by immunoblotting with a pTyr. The association of SHP-2 was determined by immunoblotting with an anti-SHP-2 antibody. The amount of IGF-IR
protein in each lane is shown in the lower row. The changes IGF-IR phosphorylation and SHP-2 recruitment after IGF-I stimulation as determined
by scanning densitometric analysis of Western immunoblots from three separate experiments is shown. **p  0.05 when the response of cells
expressing IAPc-s that were stimulated with IGF-I is compared with the response of cells expressing IAPfl.
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in the level of IGF-IR phosphorylation after 10 min exposure
to IGF-I. In contrast to control cells however, there is no
apparent reduction in IGF-IR phosphorylation after 20 min.
To confirm that the lack of SHP-2 recruitment to the IGF-IR
in the cells pretreated with B6H12 was due to specifically to
the disruption of the IAP–SHPS-1 interaction, we examined
IGF-IR phosphorylation in cells expressing IAPc-s. Figure 3B
shows that in these cells, there is no increase in the recruit-
ment of SHP-2 to the IGF-IR in response to IGF-I and this is
associated with is a significant reduction in the amount of
IGF-IR dephosphorylation observed 20 min after IGF-I stim-
ulation.
IGF-I–stimulated MAPK Activity and Cell
Proliferation Are Inhibited after Disruption of SHP-
2 Transfer
Previous studies have shown that expression of an inactive
form of SHP-2 results in inhibition of IGF-I–stimulated
MAPK, suggesting that transfer of SHP-2 to signaling mol-
ecules is necessary for IGF-I–stimulated MAPK activity
(Manes et al., 1999). To examine the consequence of the lack
of SHP-2 transfer after the disruption of IAP–SHPS-1 bind-
ing, we examined the activation of MAPK in response to
IGF-I in the presence of B6H12.
Figure 4A shows after 10 min, IGF-I treatment stimulates
a significant increase in the activation of MAPK as deter-
mined by the assessment of the dual phosphorylation of
p42/p44 MAPK (3.6  0.2-fold, mean  SEM, n  3), and
this was not significantly different from cells preincubated
with IgGi (4.4  0.3, mean  SEM, n  3). However, when
cells were preincubated with B6H12, IGF-I was unable to
stimulate a significant increase in p42/p44 MAPK phos-
phorylation (1.3  0.1-fold, mean  SEM, n  3) (p  0.05
when cells are compared with control, IGF-I–stimulated
cells).
To examine the consequence of the disruption in IAP-
SHPS-1 association on IGF-I action in SMCs we determined
the effect of B6H12 on IGF-I stimulated cell proliferation.
Figure 4B shows that in IGF-I stimulates a 2.2  0.2-fold
(mean  SEM, n  3) increase in cell proliferation after 48 h,
and this was not significantly different from cells preincu-
bated with control IgGi (2.0  0.1, mean  SEM, n  3).
However, when cells are incubated with B6H12, there is a
significant reduction in IGF-I–stimulated cell proliferation
(1.03  0.01, mean  SEM, n  3, p  0.05 compared with
cells incubated in the absence of B6H12). This inhibition in
cell proliferation is consistent with the inhibition of IGF-I
stimulated MAPK activation.
Disruption of the IAP Interaction with SHPS-1
Inhibits IGF-I–stimulated Cell Migration
We have previously reported that the preincubation of
pSMCs with B6H12 inhibits IGF-I–stimulated migration,
in part, by altering the interaction between IAP and V3
(Maile et al., 2002). To determine whether at least part of
the effect B6H12 was also due to the inhibition of IAP
binding to SHPS-1, we compared cell migration in re-
sponse to IGF-I in cells expressing IAPfl and the IAPc-s
mutant. In Figure 5A, it can be seen that IGF-I stimulated
a significant increase in pSMC migration in cells express-
ing IAPfl. However, in cells expressing the IAPc-s mutant,
IGF-I–stimulated migration is significantly reduced. In
contrast, PDGF-stimulated cell migration of the IAPc-s
cells is not significantly different compared with cells
expressing full-length IAP (Figure 5B).
Figure 4. (A) Phosphorylation of MAPK and cell proliferation
in response to IGF-I. Cells were plated and grown as described in
MATERIALS AND METHODS before a 2-h incubation  B6H12
or IgGi (both at 4 g/ml) and then treated with IGF-I (100 ng/ml)
for 10 min. The level of p42/44 MAPK phosphorylation was
determined by immunoblotting with a phosphospecific MAPK
antibody. The total amount of MAPK in each sample was deter-
mined by immunoblotting with a MAPK antibody. (B) Cells were
plated and grown as described in MATERIALS AND METHODS
before a 2-h incubation  B6H12 or IgGi (both at a concentration
of 4 g/ml) and then treated with IGF-I (100 ng/ml) for 48 h. Cell
number in each well was then determined. Each data points
represent the mean of three independent experiments. **p  0.05
when the response of cells incubated in the presence of B6H12 is
compared with cells incubated with control IgGi or in the absence
of antibody.
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DISCUSSION
The role of SHPS-1 in intracellular signaling has largely been
attributed to the recruitment of SHP-2 to the phosphorylated
tyrosines contained within ITIM motifs in the cytoplasmic
tail of SHPS-1 and the subsequent activation of its phospha-
tase activity (Fujioka et al., 1996; Takada et al., 1998). This
SHP-2 recruitment has been shown to be important for its
transfer to growth factor receptors and downstream signal-
ing molecules. The requirement of transfer of activated
SHP-2 to downstream signaling molecules for growth fac-
tors such as IGF-I to stimulate their physiological actions has
been strongly suggested by studies showing that expression
of dominant negative forms of SHP-2 result in failure to
properly activate growth factor-stimulated increases in
MAPK (Milarski and Saltiel, 1994; Noguchi et al., 1994;
(Pronk et al., 1994; Xiao et al., 1994; Yamauchi et al., 1995) and
phosphatidylinositol 3-kinase (Ugi et al., 1996; Wu et al.,
2001; Zhang et al., 2002). For IGF-I, it was specifically shown
that expression of a dominant negative SHP-2 mutant re-
sulted in a failure to activate MAPK or cell migration in
response to IGF-I (Manes et al., 1999). The results from this
study allow us to propose that 1) ligand occupancy of
SHPS-1 by IAP is necessary for IGF-I–stimulated SHPS-1
phosphorylation, and 2) the interaction between the IAP and
SHPS-1 is a key regulator of IGF-I signaling in SMCs because
disrupting the interaction leads to failure to recruit and
transfer SHP-2 and to attenuation of several IGF-I–stimu-
lated effects. Specifically, disruption of the interaction be-
tween the two proteins using two independent approaches
resulted in a loss of SHP-2 recruitment to SHPS-1 and sub-
sequent transfer to the IGF-IR, which was reflected in pro-
longed IGF-IR phosphorylation. The consequence of lack of
SHP-2 recruitment and transfer was evident in the inability
of IGF-I to stimulate MAPK activation and subsequently cell
proliferation or cell migration. Although not specifically
examined in this study, we cannot rule the possibility that
the disruption in SHP-2 recruitment may also result in an
inhibition of the PI 3 kinase pathway and that this contrib-
utes to the inhibition of cell migration in response to IGF-I.
The consequence of disrupting the interaction between
SHPS-1 and IAP has been studied in other systems that have
not been shown to be dependent upon growth factor recep-
tor activation. These studies have shown that anti-IAP
monoclonal antibodies block the attachment of cerebellar
neurons, erythrocytes, and thymocytes to a substratum con-
taining P84 (a brain homolog of SHPS-1) (Jiang et al., 1999;
Seiffert et al., 1999). That this interaction might play a role in
cell-to-cell attachment was substantiated in experiments that
demonstrated that the expression of the extracellular do-
main of SIRP in SIRP negative cells supported adhesion of
primary hematopoietic cells and this interaction was inhib-
ited by anti-IAP monoclonal antibodies (Vernon-Wilson et
al., 2000). In general, these studies have analyzed the role of
this interaction in mediating intercellular attachment. How-
ever, cell adhesion molecules that are expressed on the cell
surface such as integrins are important not only for cell
attachment but also for the regulation of cell proliferation,
survival, and differentiation (Mauro et al., 2003). The regu-
lation of growth factor signaling by integrin receptors has
been well documented. We have previously reported that
ligand occupancy of V3 is necessary for IGF-I–stimulated
receptor signaling and a similar cooperative relationship
between integrin receptors and the PDGF, epidermal growth
factor, and fibroblast growth factor growth factor receptors
has also been described (Miyamoto et al., 1996). Previous
studies (Kuzmenko et al., 1998; Andre et al., 1999; Mauro et
al., 2001; Maile et al., 2002) have explored the role of growth
factor receptors in activating cell adhesion molecule affinity,
but there is minimal published data regarding the ability of
cell adhesion molecules to regulate growth factor action. The
results from this study demonstrate that the interaction of
the cell-to-cell adhesion molecules (e.g., IAP and SHPS-1)
plays an important regulatory role in IGF-I signaling. Given
the importance of cell-to-cell adhesion molecules in regulat-
ing cell function, it is tempting to speculate that the regula-
tion of IGF-I signaling by cell-to-cell adhesion molecules is a
general mechanism for regulating IGF-I actions. Although
PDGF signaling was not affected by disruption of the IAP–
SHPS-1 interaction, this finding does not exclude the possi-
bility that other cell-to-cell adhesion molecules could play a
similar role in regulating signaling by PDGF and other
growth factors.
SHPS-1 phosphorylation in macrophages was increased
after contact with red blood cells expressing IAP when they
were compared with red blood cells not expressing IAP
(Oldenborg et al., 2000). That result suggested that IAP bind-
ing to SHPS-1 was stimulating phosphorylation. In this
study, we have demonstrated that ligand occupancy of
SHPS-1 by IAP is required for IGF-I–stimulated SHPS-1
phosphorylation. SHPS-1 has been shown to be phosphory-
lated directly by the insulin receptor kinase (Fujioka et al.,
1996). Given the homology between the tyrosine kinase do-
Figure 5. IGF-I- and PDGF-stimulated cell
migration in cells expressing full-length IAP
and IAPc-s. Confluent cells were wounded
then incubated  IGF-I (100 ng/ml) (A) or
PDGF (10 ng/ml) (B) for 48 h. The number of
cells migrating across the wound edge in at
least five preselected regions was counted.
Each data point represents the mean  SEM
of three independent experiments. **p  0.05
when migration of cells expressing IAPfl in
the presence of IGF-I or PDGF is compared
with incubation in SFM alone or when cells
expressing IAPc-s stimulated with PDGF are
compared with SFM alone.
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mains in the insulin and IGF-IR (e.g., 84%), it is possible that
SHPS-1 is also a direct substrate for the IGF-IR kinase. If the
IGF-IR kinase is directly phosphorylating SHPS-1, then IAP
binding to SHPS-1 could modulate this process by either
translocating SHPS-1 into proximity with the IGF-IR kinase
or by altering the conformation of the SHPS-1 cytoplasmic
domain, thus making its tyrosines residues more accessible
to phosphorylation by the IGF-IR kinase. Using either model
disruption of the SHPS-1–IAP interaction would be pre-
dicted to have the opposite effect. Because PDGF could still
stimulate SHPS-1 phosphorylation in the absence of IAP
binding to SHPS-1, this suggests that PDGF and IGF-I may
stimulate SHPS-1 phosphorylation via two different kinases.
SHPS-1 phosphorylation in response to integrin engagement
has been shown to be mediated via a Src family kinase
(Fujioka et al., 1996). Although the kinase responsible for
PDGF-stimulated phosphorylation has not been described,
our results suggest that the phosphorylation of SHPS-1 by
IGF-I and PDGF is differentially regulated by SHPS-1 ligand
occupancy.
By virtue of its ability to stimulate SMC migration and
proliferation, IGF-I has been proposed to be an important
contributor to the development of atherosclerosis (Jones et
al., 1996). In mice in which IGF-I was overexpressed in
SMCs, there was an increase in the rate of neointimal for-
mation after carotid injury that seemed to have resulted
from increased SMC proliferation and migration. The effect
was apparent despite equivalent levels of serum IGF-I in
plasma compared with control animals, suggesting a para-
crine effect of locally produced IGF-I (Zhu et al., 2001). Given
the apparent role of IGF-I in the development of atheroscle-
rosis and the effect of this interaction on IGF-I signaling, it is
likely that this system may play a role in the development of
atherosclerosis and disruption of the interaction of IAP–
SHPS-1 may represent a novel therapeutic strategy to spe-
cifically inhibit IGF-I action. Current approaches to target
IGF-I signaling have focused on blocking the activity of the
receptor itself by using antibodies or peptides. Disrupting
cell-to-cell adhesion molecule interactions that specifically
inhibit growth factor signaling offers a novel therapeutic
strategy. It is also possible that this approach, which uses a
distinct molecular mechanism, might work in synergy with
other strategies.
In summary, our results have shown that the interaction
of two specific cell surface proteins that have been shown to
mediate cell adhesion is required for IGF-I–stimulated
SHPS-1 phosphorylation and SHP-2 recruitment in SMCs.
Disruption of this interaction results in impairment of IGF-I
signaling and biological actions. Further studies will be nec-
essary to understand the effect of specific ligands for both of
these transmembrane proteins on their interaction and their
effect on IGF-IR signaling. Because IAP also binds to V3 it
is also possible that these three proteins function coordi-
nately as a unit. Analyzing how ligand occupancy of each
component alters signaling by the entire complex is there-
fore an important goal of future studies.
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